Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022

Rhea-AI Summary

Assembly Biosciences announces the addition of Professor Michael P. Manns, MD, to its leadership team, focusing on hepatitis B and delta viruses. A webcast is scheduled for March 31, 2022, to unveil a new research program targeting HBV and HDV via an innovative orally bioavailable small-molecule approach. Key speakers include Manns, Assembly Bio CEO John McHutchison, and Chief Scientific Officer William Delaney. The company aims to advance therapies for the 296 million individuals with HBV globally, emphasizing the urgent need for treatment options.

Positive

• Introduction of a new research program focusing on a novel treatment for HBV and HDV.
• Recruitment of an international expert in liver diseases to enhance expertise.
• Commitment to addressing the needs of 296 million people living with HBV worldwide.

Negative

• None.

Assembly Bio leadership team will be joined by Professor Michael P. Manns, MD, an international expert in liver diseases including hepatitis B virus (HBV) and hepatitis delta virus (HDV)

SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, will host a webcast on Thursday, March 31, 2022 from 8:00 – 9:00 am PT/11:00 am – 12:00 pm ET to introduce its new research program focused on a novel, orally bioavailable small-molecule approach to inhibit entry of HBV and hepatitis delta virus (HDV).

The program will feature presentations, discussion and Q&A with the following speakers:

• Professor Michael P. Manns, MD, President of Hannover Medical School, Hannover, Germany
  • Hepatitis Delta: The greatest current unmet need in hepatology
• John McHutchison, AO, MD, Chief Executive Officer and President at Assembly Bio
  • Assembly Bio strategy, leveraging expertise in viral disease to expand portfolio
• William Delaney, PhD, Chief Scientific Officer at Assembly Bio
  • Molecular virology of HBV & HDV and overview of Assembly Bio’s new research program targeting HBV/HDV entry

The live webcast will be available in the Events & Presentations page in the Investors section of Assembly Bio’s website and a replay will be accessible following the event. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.

About Assembly Biosciences
Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 296 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies for HBV cure and research programs focused on the discovery of additional novel antiviral mechanisms for HBV and other viral diseases. For more information, visit assemblybio.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s clinical collaboration agreements, in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; continued development and commercialization of Assembly Bio’s HBV product candidates, if successful, in the China territory will be dependent on, and subject to, Assembly Bio’s collaboration agreement governing its HBV-related activity in the China territory; Assembly Bio’s ability to maintain financial resources necessary to continue its clinical studies and fund business operations; any impact that the COVID-19 pandemic may have on Assembly Bio’s business and operations, including initiation, enrollment and continuation of its clinical studies or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investor and Corporate:
Jason Okazaki
Chief Operating Officer
(415) 951-3946
jokazaki@assemblybio.com

Media:
Sam Brown Inc. 
Audra Friis 
(917) 519-9577 
ASMBMedia@sambrown.com

FAQ

What new research program is Assembly Biosciences launching for hepatitis B virus (HBV)?

Assembly Biosciences is launching a new research program focused on a novel, orally bioavailable small-molecule approach to inhibit HBV and hepatitis delta virus (HDV) entry.

Who is Professor Michael P. Manns and what is his role at Assembly Biosciences?

Professor Michael P. Manns is an internationally recognized expert in liver diseases, joining Assembly Biosciences' leadership team to enhance their focus on HBV and HDV.

When is the webcast for Assembly Biosciences' new research program?

The webcast for Assembly Biosciences' new research program is scheduled for March 31, 2022, from 8:00 AM to 9:00 AM PT.

How does Assembly Biosciences plan to address the need for HBV treatments?

Assembly Biosciences aims to develop finite and curative therapies as part of its strategy to meet the needs of the 296 million people living with hepatitis B virus (HBV) worldwide.

What are the key focuses of the upcoming webcast hosted by Assembly Biosciences?

The webcast will feature discussions on Assembly Biosciences' strategy, the molecular virology of HBV and HDV, and the new research program targeting HBV/HDV entry.